Answers are grounded in this paper and cite their sources.
Intratumoral vaccine chimera (iVAC) is a protein level immune activation strategy that co delivers PD-L1 degrading agents and exogenous antigen peptides to tumor cell lysosomes through covalent nanobodies. It can complete antigen cross presentation while degrading PD-L1, and no off target mutations were observed in the detection as it does not involve genome editing. This article takes this as a zero-genome-risk reference and systematically compares existing data on iVAC and CRISPR tumor immune strategies from three dimensions: safety, persistence, and targeting depth. The results showed that the CRISPR strategy has accumulated preliminary clinical evidence in targeting intracellular driven mutations and long-term effectiveness of single editing (BRL-201 has a four-year complete response rate of 85.7% and an estimated five-year progression free survival rate of 40.6%), and off target detection methods continue to improve (TOPO seq found topology induced off target, and base edited NK cell products have obtained clinical approval); IVAC relies on pre stored CMV memory T cells, with transient modifications and a lack of long-term data. The existing evidence suggests that the two strategies may complement each other rather than replace each other in terms of security features, persistence, and depth of action. In the future, it is necessary to accumulate long-term human data on iVAC, promote the validation of CRISPR editing tools in solid tumors, and conduct clinical exploration of prospective combination therapies.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: